D
Regeneron Pharmaceuticals, Inc. REGN
$538.11 -$9.25-1.69% NASDAQ
Recommendation
Prev Close
$525.00
Volume
10
Avg Vol (90D)
1,233,826
Market Cap
$55.47B
Dividend & Yield
$1.76(0.34%)
52-Week Range
$476.49 - $1,211.20
P/E (TTM)
13.36
EPS (TTM)
$39.29
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025
5/15/2025 - MarketBeat
23andMe's $305M Sale To Co-Founder Wojcicki Approved: California Loses Legal Battle Over DNA Privacy
7/8/2025 - Stocktwits News Feed
The biggest retail & restaurant bankruptcies of 2025 (so far)
7/7/2025 - TheStreet.com
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
7/7/2025 - CNW Group - News Releases
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
7/7/2025 - PR Newswire
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
7/7/2025 - Zacks Investment Research
13 Most Undervalued Large Cap Stocks to Buy According to Analysts
7/7/2025 - Insider Monkey
China Universal Asset Management Co. Ltd. Has $16.26 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
7/7/2025 - MarketBeat
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
7/7/2025 - CNW Group - News Releases
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
7/7/2025 - PR Newswire
Impax Asset Management Group plc Sells 1,385 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
7/7/2025 - Ticker Report
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Trimmed by Impax Asset Management Group plc
7/7/2025 - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of "Moderate Buy" by Analysts
7/7/2025 - MarketBeat
Bank of New York Mellon Corp Increases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
7/6/2025 - MarketBeat
Calamos Advisors LLC Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
7/6/2025 - MarketBeat
Keybank National Association OH Has $972,000 Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
7/6/2025 - Ticker Report
Moody Aldrich Partners LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
7/5/2025 - Ticker Report
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Braun Stacey Associates Inc.
7/5/2025 - MarketBeat
2 Beaten-Down Stocks to Buy and Hold
7/5/2025 - Fool.com Headlines
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by IFM Investors Pty Ltd
7/5/2025 - MarketBeat
Principal Financial Group Inc. Has $82.21 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
7/5/2025 - MarketBeat
Teacher Retirement System of Texas Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
7/5/2025 - MarketBeat
The 23andMe Court Got It Right; Is that Wrong?
7/5/2025 - Credit Slips
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by GF Fund Management CO. LTD.
7/4/2025 - MarketBeat
Best Biotech Stocks to Buy in 2025
5/13/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$14.09B
EBITDA (TTM)
$4.46B
EBIT (TTM)
$3.96B
Net Income (TTM)
$4.50B
Balance Sheet
Total Assets (Q)
$37.55B
Total Debt (Q)
$2.70B
Total Liabilities (Q)
$8.16B
Book Value Per Share (Q)
$277.50
Cash Flow
Cash from Operations (TTM)
$3.95B
Cash from Investing (TTM)
-$133.50M
Cash from Financing (TTM)
-$3.34B
Net Change in Cash (TTM)
$483.20M
Filings
Filing Date
Tuesday, April 29, 2025
Period Date
Monday, March 31, 2025
Next Filing
Beginning of August (est)
Price History
Loading...
Beta
0.76
7-Day Total Return
5.57%
30-Day Total Return
-9.32%
60-Day Total Return
-11.75%
90-Day Total Return
-22.57%
Year to Date Total Return
-24.55%
1-Year Total Return
-48.95%
2-Year Total Return
-24.85%
3-Year Total Return
-9.37%
5-Year Total Return
-11.42%
52-week Low
Jun 05, 2025 - $476.49
52-week High
Aug 27, 2024 - $1,211.20
Valuation
Market Cap
$55.47B - Large Cap
Enterprise Value
$40.55B
Price/Sales (TTM)
4.14
Price/Book (Q)
1.89
Dividends and Shares
Shares Outstanding
111.20M
Dividend Per Share (Most Recent)
$0.88
Dividend Per Share (TTM)
$1.76
Corporate Info
Website
www.regeneron.com
Phone Number
914 847 7000
Address
777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
Country
United States
Year Founded
1988
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to... more
NASDAQ 07/07/2025 4:00PM Eastern Quotes delayed